Institut Curie - Site Paris
- Address
- lock Available on a paid plan
Neoplasms and Oncology Research at Institut Curie - Site Paris
This research site focuses on cancer studies across several neoplastic diseases, with trials aimed at improving treatment outcomes, testing new anti-cancer combinations, and refining supportive approaches for patients with advanced or hard-to-treat tumors.
- Studies in breast neoplasms are exploring new treatment strategies for advanced disease, including hormone receptor-positive and HER2-negative cancers.
- Research in non-small cell lung cancer is evaluating novel therapy combinations for KRAS G12C-mutant tumors that are either resected or unresectable.
- Trials in Ewing sarcoma are assessing ways to improve outcomes for newly diagnosed metastatic disease, including better use of chemotherapy and radiotherapy.
Overall, the clinical research program at Institut Curie is centered on finding more effective and better-tolerated treatments for aggressive cancers, while also examining how treatment selection can improve outcomes in metastatic disease and after surgery.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 17 therapeutic areas and 15 of 299 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 293 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 75 by active trials.
- 1Unicancer10active
lock +74 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB16trials
lock +43 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Institut Curie - Site Paris
lock Showing 1 of 256 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| "DEMETER": Milademetan and fulvestrant in GATA3-mutant, ER-positive, HER2-negative advanced or metastatic breast cancer patients: a multicenter phase II trial | Institut Curie | Phase II | Not Recruiting | Oct 2023 | Nov 2023 |
IMP list
lock Showing 1 of 299 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Carboplatin | 49 | Unknown | 2016-11-17 | 2026-06-23 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.